Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday
Key Points
The market didn't react positively to the diagnostics specialist's third-quarter earnings report.
It beat on both the top and bottom lines, but growth rates were low.
- 10 stocks we like better than Bio-Rad Laboratories ›
Healthcare diagnostics product supplier Bio-Rad Laboratories (NYSE: BIO) notched twin beats in its just-released third quarter, but that wasn't enough for a choosy stock market. Investors sold out of the company's shares in the wake of that earnings report to leave it with an over 3% loss on Thursday. This was a steeper fall than the 0.9% decline of the benchmark S&P 500 index.
Modest improvements
Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) rose at a slightly higher rate, advancing by 8% to just under $61 million. On a per-share basis, that non-GAAP (adjusted) bottom line figure was $2.26.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Although Bio-Rad didn't post explosive growth, those numbers were high enough to beat the consensus analyst estimates. Collectively, prognosticators following the company had anticipated its top line would land at $652.2 million and adjusted net income would be $1.95 per share.
In the company's earnings release, it attributed the thin growth numbers to tightening biotech funding and "ongoing challenges in academic research."
Guidance maintained
It doesn't appear as if those roadblocks are going to disappear in the proximate future. Bio-Rad maintained its guidance for the entirety of 2025 in which it's forecasting revenue growth flat to 1% above the 2024 result. Its adjusted operating margin should fall at 12% to 13%, the company added.
Should you invest $1,000 in Bio-Rad Laboratories right now?
Before you buy stock in Bio-Rad Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bio-Rad Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $593,442!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,269,127!*
Now, it’s worth noting Stock Advisor’s total average return is 1,071% — a market-crushing outperformance compared to 196% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of October 27, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
